CrystalGenomics, Inc.
KOSDAQ 083790.KQ
CrystalGenomics, Inc. Share Price on January 14, 2025: USD 1.63
-
CrystalGenomics, Inc. 52-week high Share Price is USD 3.05 on March 18, 2024, which is 87.54% above the current Share Price.
-
CrystalGenomics, Inc. 52-week low Share Price is USD 1.55 on October 16, 2024, which is -4.41% below the current Share Price.
-
CrystalGenomics, Inc. average Share Price for the last 52 weeks is USD 2.00.
| Date | Share Price | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) |
|---|
| CEO | Dr. Joong-Myung Cho Ph.D. |
| IPO Date | Jan. 6, 2006 |
| Location | South Korea |
| Headquarters | Tower A, Korea Bio Park |
| Employees | 65 |
| Sector | Health Care |
| Industries | |
CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial. In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services. The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was founded in 2000 and is headquartered in Seongnam, South Korea.
Past 5 years
USD 83.61
USD 209.72
USD 108.37
USD 3.70
USD 1.92
StockViz Staff
January 15, 2025
Any question? Send us an email